Form 4: Organon Executive Granted 65,616 Restricted Stock Units

Organon & Co.'s Interim Head of Manufacturing & Supply, Juliana Drinane, was granted 65,616 Restricted Stock Units.

Summary

• Juliana Drinane, Interim Head of Manufacturing & Supply at Organon & Co. (OGN), was granted 65,616 Restricted Stock Units (RSUs).
• Each RSU converts into one share of Organon & Co. common stock.
• The RSUs were granted on November 13, 2025, and will vest in three equal installments.
• Vesting dates are scheduled for November 13, 2026, November 13, 2027, and November 13, 2028.

Sentiment

Score: 7

Explanation: The grant of equity to a key executive is generally a positive event, signaling management alignment with shareholder interests and providing long-term incentives, though it is a routine compensation disclosure.

Positives

• The grant of 65,616 Restricted Stock Units aligns the interests of the Interim Head of Manufacturing & Supply with those of shareholders.
• This equity compensation serves as an incentive for long-term performance and retention of key management personnel.

Future Outlook

The vesting schedule for the Restricted Stock Units over the next three years indicates a commitment to retaining key management and incentivizing long-term performance, aligning executive interests with future company growth.

Industry Context

The grant of Restricted Stock Units is a common practice in the pharmaceutical and biotechnology industries for executive compensation, aiming to attract, retain, and motivate key talent by linking their financial success to the company's stock performance.

Comparison to Industry Standards

• Equity grants, particularly Restricted Stock Units with multi-year vesting schedules, are a standard component of executive compensation packages across publicly traded companies, including those in the healthcare sector.
• The structure of this grant, with vesting over three equal installments, is typical for long-term incentive plans designed to promote executive retention and align with shareholder value creation.

Stakeholder Impact

• Shareholders: The grant aligns the executive's financial interests with shareholder value creation, potentially leading to more focused long-term decision-making.
• Employees: This type of compensation can signal stability in executive leadership and a commitment to rewarding performance, potentially boosting morale.

Next Steps

• The RSUs will vest in three equal installments on November 13, 2026, November 13, 2027, and November 13, 2028.

Key Dates

Keywords

Organon, OGN, Restricted Stock Units, RSU, Executive Compensation, Insider Transaction, Form 4, Equity Grant